These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27067661)

  • 1. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.
    Proietti M; Senoo K; Lane DA; Lip GY
    Sci Rep; 2016 Apr; 6():24376. PubMed ID: 27067661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
    Senoo K; Proietti M; Lane DA; Lip GY
    Am J Med; 2016 Jun; 129(6):600-7. PubMed ID: 26482233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation.
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
    Sci Rep; 2017 Sep; 7(1):12066. PubMed ID: 28935868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
    Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
    J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.
    Senoo K; Lip GY
    Int J Cardiol; 2016 Oct; 221():379-82. PubMed ID: 27409565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    Am J Med; 2018 May; 131(5):574.e13-574.e27. PubMed ID: 29274754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
    Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
    J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
    O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
    Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study.
    Chao TF; Lip GYH; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Chen SA
    Int J Cardiol; 2018 Mar; 254():157-161. PubMed ID: 29407081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
    Lip GY; Frison L; Halperin JL; Lane DA
    J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores.
    Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Romiti GF; Marin F; Lip GYH
    J Am Heart Assoc; 2018 Sep; 7(18):e009766. PubMed ID: 30371183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: A PRISMA-compliant article.
    Zeng J; Yu P; Cui W; Wang X; Ma J; Zeng C
    Medicine (Baltimore); 2020 Jun; 99(25):e20782. PubMed ID: 32569222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
    Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
    Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Sanmartin Fernández M; Arribas F; Masjuan J; Barrios V; Cosin-Sales J; Freixa-Pamias R; Recalde E; Pérez-Cabeza AI; Manuel Vázquez Rodríguez J; Ràfols Priu C; Anguita Sánchez M; Lip GYH; Marin F
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):38-46. PubMed ID: 36318457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
    Lip GYH; Lane DA; Buller H; Apostolakis S
    Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
    Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
    Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.